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Abstract
Lung fibrosis is characterised by the accumulation of extracellular
matrix within the lung and is secondary to both known and
unknown aetiologies. This accumulation of scar tissue limits gas
exchange causing respiratory insufficiency. The pathogenesis of
lung fibrosis is poorly understood, but immunologic-based
treatments have been largely ineffective. Despite this,
accumulating evidence suggests that innate immune cells and
receptors play important modulatory roles in the initiation and
propagation of the disease. Paradoxically, while innate immune
signalling may be important for the pathogenesis of fibrosis, there
is also evidence to suggest that innate immune function against
pathogens may be impaired, leading to dysregulated and/or
impaired host defence. This review summarises the evidence for
this pathologic two-way street, highlights new concepts of
pathogenesis and recommends future directions for research
emphasis.
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LUNG ARCHITECTURE
The lung is reportedly made up of dozens of cell
types and has evolved architecturally into a series
of branching airways and alveoli to support
efficient gas exchange (Figure 1).1 The ability of
the lung to mediate gas exchange requires that
the alveoli are characterised by thin layers of type
I alveolar epithelial cells (AECs) in close
approximation to capillaries to allow efficient cell
permeable transfer of oxygen and carbon
dioxide.1,2 The structure of the lung is supported
by a meshwork of fibroblasts, matrix and
basement membrane structures.3 Type II AECs are
important as progenitors for new type I AECs, as a
source of surfactant needed to reduce surface
tension during respiration and also as a source of
host defence proteins.4 Finally, the airways are
patrolled by innate immune cells including tissue-
resident alveolar macrophages. At homeostasis,
there is a fine balance that keeps the airspaces
open and cleared of pathogens and debris.5
However, following insult or injury to the AECs,
exudative inflammation can occur to recruit
numerous immune cells. Furthermore, alveolar
and endothelial leak postinjury provides a source
of profibrotic mediators including growth factors
and coagulation components. In most cases, this
response is limited and the lung returns to
homeostasis, but in other cases, the repair
response can become dysregulated leading to
lung fibrosis.6–8
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LUNG FIBROSIS
Lung fibrosis is a condition that is characterised by
accumulation of extracellular matrix (ECM) within
the lung. When progressive, the accumulating ECM
can cause alveolar distortion and loss of gas
exchange, eventually leading to respiratory
insufficiency. The exact aetiology of most fibrotic
lung diseases is unknown (i.e. idiopathic), although
there are genetic mutations (e.g. in telomerase or
surfactant protein C genes) that can lead to fibrosis
and there are environmental insults (e.g. asbestos
and silica) that are also known to cause
development of lung fibrosis. The most common
form of idiopathic interstitial pneumonia is
idiopathic pulmonary fibrosis (IPF), and this form of
lung fibrosis in humans is the most well-studied.9
IPF has a median survival of 2–3 years, and the
disease is more prevalent in older individuals and
more common in men than in women. IPF is a
chronic and progressive disease believed to be
mediated by microinjuries to the lung AECs,
chronic inflammation, accumulation of fibroblasts
and myofibroblasts, dysregulated wound repair
and aberrant deposition of ECM. The clinical course
of the disease is highly heterogeneous with some
patients showing slow progression and others
showing rapid deterioration after events known as
acute exacerbations which are believed to be
noninfectious.
Despite decades of study, the pathogenesis of
pulmonary fibrosis is poorly understood, and
there has been ongoing controversy over the role
that immune mechanisms may play in disease
progression. Most notably, the failure of many
immunomodulatory therapies (e.g. augmentation
of interferon gamma (IFNc),10 neutralisation of
tumor necrosis factor alpha (TNF-a)11 and the
early stoppage of the PANTHER clinical trial
designed to test prednisone, azathioprine and N-
acetylcysteine due to harm12 have led many to
conclude that IPF is not caused by
immunopathology. However, there has also been
an explosion of both human and animal data in
recent years to suggest that innate immune cells,
in particular, may modify the pathogenesis of
lung fibrosis. We will briefly review evidence to
support a role for innate immune receptors,
inflammasomes, neutrophils and macrophages in
mediating development of lung injury and
propagation of lung fibrosis. In addition, the fact
that immune-suppression worsened outcomes for
IPF patients12 highlights the possibility that lung
fibrosis may also be modulated, in part, by a
weakened immune system. Thus, we will also
consider how altered innate immune signalling
may lead to recurrent infections and/or alterations
in the microbiome which may promote disease.
Because lung fibrosis appears to be a final
common endpoint for a number of diverse
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Figure 1. The cellular architecture of the lung. Gas exchange occurs in the alveoli which are surrounded by a network of capillaries. The alveolar
airspace is defined predominantly by type I alveolar epithelial cells (AECIs), which are thin and elongated to facilitate the diffusion of oxygen and
carbon dioxide. Type II alveolar epithelial cells (AECIIs) function primarily as progenitor cells for AECIs and to secrete surfactant and host defence
proteins. Fibroblasts support the structure of the lung and produce extracellular matrix, which contributes to the development of fibrosis. Finally,
alveolar macrophages (AMs) reside in the alveolar airspace and are important for maintaining tissue homeostasis and initiating an immune
response to respiratory pathogens.
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injuries and conditions, we will also explore the
impact of innate immunity on two other forms of
lung fibrosis, namely silica-induced toxicity and
the development of pneumonitis and fibrosis
post-stem cell transplant and will discuss both
preclinical models and data from patients with
these conditions.
PRECLINICAL MODELS TO BE
DISCUSSED
Because humans with IPF are generally diagnosed
with end-stage disease, it can be a challenge to
study the natural progression of lung fibrosis in
humans. Therefore, a number of animal models
have been developed that involve chemically
induced lung injury, particulates, genetically
modified mice, viral infections and radiation. In
this review, we will restrict our analyses to three
animal models of lung fibrosis, namely
intratracheal delivery of bleomycin, silica-induced
lung fibrosis, and a model of viral-induced
pneumonitis and fibrosis following stem cell
transplant to highlight the influences of innate
immunity on initiation and progression of disease.
While these animal models are useful for studies
of disease mechanisms that we hope are shared
between rodents and humans, it should be
acknowledged that none of these animal models
fully recapitulate the natural history, time course,
histology and pathogenesis of the human
diseases.
ROLE OF INNATE IMMUNE RECEPTORS
IN LUNG FIBROSIS
A number of innate immune receptors have been
implicated in the pathogenesis of lung fibrosis,
and many of these receptors are expressed on
both structural and immune cells. One family of
receptors is known as pattern or pathogen
recognition receptors (PRRs), and they sense
‘danger’ in the form of injury or infection by
recognition of pathogen-associated molecular
patterns (PAMPs) or danger-associated molecular
patterns known as DAMPs. This PRR family
includes Toll-like receptors (TLRs), nucleotide-
binding oligomerisation domain receptors
(NOD-like receptors or NLRs), C-type lectin
receptors, retinoic acid-inducible gene 1(RIG-1)-
like receptors (RLRs) and cytosolic DNA receptors.
PAMP ligands for PRRs include substances such as
lipopolysaccharide (LPS), peptidoglycan and
flagellin, which are components of bacterial
surfaces, but also include unique pathogen
genomic structures such as double-stranded RNA
and CpG-rich DNA that is enriched in microbes. In
contrast, the DAMP ligands include substances
such as heat-shock proteins13 and fragments of
the ECM such as small leucine-rich proteoglycans,
as well as glycosaminoglycans which we recently
reviewed.14 Interactions of ligands with PRRs
ultimately results in signal transduction that
changes transcription factors to influence gene
expression. For example, many PAMPs induce
expression of IL-6, IL-1b and CXCL2/8 via induction
of nuclear factor kappa-light-chain-enhancer of
activated B cells (NF-kB) to promote inflammatory
responses. Similarly, DAMPs derived from ECM can
also promote inflammation. For example,
fibronectin is a component of provisional matrix
and various alternatively spliced forms of
fibronectin can trigger TLR4-dependent NFjB-
mediated release of pro-inflammatory cytokines
from fibroblasts.15 Another particularly well-
studied example is the breakdown of high
molecular weight hyaluronan (HMW-HA)
following injury into low molecular weight forms
(LMW-HA) that can trigger release of pro-
inflammatory mediators16 and also down-regulate
anti-inflammatory signalling via adenosine A2a
receptors.17 While these interactions of LMW-HA
with cells like macrophages promote injury and
fibrosis, binding to TLR4 on alveolar epithelial
cells promotes alveolar repair,18 thus helping to
restore lung homeostasis. Additionally, production
of new HMW-HA during repair may actively
suppress further inflammation by activating T
regulatory cells.19 When considered together,
evidence suggests that signalling via innate
immune receptors can play both pathologic and
protective roles. While this is likely mediated in
part by the kinetics of ligand generation
postinjury, there is still much we do not
understand about the switch from pro-injury to
pro-resolution phases.
THE INFLAMMASOME IN LUNG
FIBROSIS
The inflammasome is the name given to a
multimeric collection of proteins that assemble in
response to DAMPs and PAMPs to activate caspase
1 to allow cleavage of pro-IL-1b and pro-IL-18 into
their biologically active forms. There are two main
steps involved in activating inflammasomes. The
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first step is the priming step, and it is mediated by
TLR activation to upregulate NF-kB and induce
transcription of inflammasome component genes
and also to increase the transcription of pro-IL-1b.
The second step is the assembly of the multiprotein
complex and activation of caspase 1. Release of
PAMPs and DAMPs caused by profibrotic injury or
infection leads to inflammasome activation, and
there are several different kinds of inflammasome
scaffolds that can form. Interestingly, it has been
suggested that as fibrosis progresses and the lung
stiffens, the increased mechanosensing by cells in
the lung may lead to ongoing inflammasome
activation as a way to perpetuate lung fibrosis.20
For example, vimentin has recently been identified
as important for inflammasome activation and mice
deficient in vimentin are protected from
bleomycin-induced fibrosis and do not stimulate IL-
1b production in response to bleomycin.21 This idea
of mechanical feed forward innate immune
activation is an interesting hypothesis about how
fibrosis becomes progressive. Another mystery in
the field of IPF research is why the disease is more
prevalent in aged individuals. In this regard, it is
interesting that the NLRP3 inflammasome is
activated in the lung in response to bleomycin22
and shows enhanced activation in aged mice
relative to young mice.23 The NLRP3 inflammasome
has also been shown to promote fibroblast
activation in response to oxidant injury22 and
NRLP3/ mice are protected from bleomycin-
induced fibrosis.23 Thus, ageing may predispose
mice to worse fibrotic outcomes because they have
a lower threshold for inflammasome activation.
In terms of silica-induced fibrosis,
inflammasome activation in macrophages that
take up the silica particles is well defined as a
critical mediator of the pathogenesis of this
disease (e.g. 24–26). Formation of the NALP3 or
NLRP3 inflammasome and pathologic release of
IL-1b is believed to be triggered via the lysosomal
damage caused by the uptake of the silica.25,27
Similarly, in terms of murine gammaherpesvirus
(cHV-68)-induced pneumonitis and fibrosis post-
stem cell transplant, the elevated production of
prostaglandin E2 that is caused by epigenetic
alterations post-bone marrow transplant28 has
recently been shown to promote prolonged
signal 1 for inflammasome activation.29 Thus,
the enhanced lung injury and prolonged
inflammation related to IL-1b release is likely
important in the pathogenesis of all of these
models of lung fibrosis.
OTHER IMMUNE-RELATED GENES AND
FIBROSIS
In addition to the pro-inflammatory signalling by
PAMPs and DAMPs described above, genetic studies
have suggested that other immune-modifying
genes may also play a role in modulating lung
fibrosis, through various mechanisms. For example,
the rs5743890 polymorphism in the TOLLIP gene is
associated with increased susceptibility to IPF,
increased mortality and reduced expression of this
protein, which normally functions as a negative
regulator of TLR signalling.30 Similarly, the gain-of-
function mutation in the mucin MUC5B gene
promoter (rs35705950) leads to overexpression of
mucin in the lung and accumulation in terminal
bronchioles.31 Mucin is believed to play an
important host defence function by trapping
inhaled particles and pathogens to allow for
mucociliary clearance. Some investigators have
hypothesised that abnormal accumulation of the
protein may overwhelm the mucociliary clearance
allowing toxic particles and pathogens to
accumulate and be localised next to lung AECs
where they may be a source of recurrent injury. In
support of this, a mouse genetically engineered to
overexpress the mucin, MUC5B, was found to have
enhanced bleomycin-induced lung fibrosis32 and
these mice display defective mucociliary clearance.
Such targeted injury to the AECs may promote
fibroproliferation in an attempt at repair.
Furthermore, as will be highlighted below,
alterations in mucin levels could change the carbon
sources within the lung and lead to dysbiosis of the
lung microbiota as an additional mechanism for
promoting lung fibrosis.
INNATE IMMUNE CELLS AND THE
PATHOGENESIS OF LUNG FIBROSIS
Polymorphonuclear leucocytes (PMNs)
In addition to innate immune receptors driving
fibrotic pathogenesis, there is also evidence for
participation by innate immune cells themselves.
Neutrophils or PMNs are short-lived effector cells
that are recruited to sites of injury where they
may contribute to lung injury and/or
fibroproliferation via the release of proteolytic
enzymes such as neutrophil elastase (NE). PMNs
are recruited via the release of chemokines,
particularly CXCL2/CXCL8, or leukotriene B4
(LTB4) induced by injury. The presence of
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increased numbers of PMNs in the
bronchoalveolar lavage fluid (BALF) portends a
poor prognosis for IPF patients.33 Recently, a
prospective study also demonstrated that excess
PMNs in the blood of IPF patients also predicted
worse outcomes and that this enhanced
neutrophilia may occur because endothelial
colony-forming cells isolated from IPF patients
secreted IL-8/CXCL8, a known PMN-recruiting
chemokine.34 This study also noted PMNs present
in histologic analyses of IPF lungs. Excessive PMN
degranulation or necrosis can lead to the release
of many proteolytic enzymes including NE. It is
likely this proteolytic enzyme is critical for
promoting fibrogenesis because NE-deficient
mice have reduced levels of fibrosis in response
to bleomycin even though these mice showed
similar numbers of PMNs recruited to the
airspaces as did control mice.35 Conversely,
histone deacetylase inhibitors that cause
significant inhibition of leukotriene A4
hydrolase, a key enzyme needed to generate the
PMN-chemotactic lipid, LTB4, can reduce the
initial PMN inflammation seen in response to
bleomycin and lessen development of lung
fibrosis.36
It is also likely that the proteolytic enzymes
released by PMNs help to activate other key
fibrotic cytokines such as transforming growth
factor (TGF)b because bleomycin-treated NE/
mice or mice treated with a NE inhibitor,
sivelestat, had reduced levels of TGFb.35,37 In vitro,
NE has been shown to promote fibroblast
proliferation and differentiation into
myofibroblasts.38 Myofibroblasts are a contractile
and highly synthetic mesenchymal cell type
believed to be a hallmark of fibrotic tissue
disease. Another mechanism by which PMNs may
promote lung fibrosis is via release of the cytokine
IL-17 during the process of NETosis when PMNs
form neutrophil extracellular traps (NETs) that
consist of decondensed chromatin, various
granules and antimicrobial peptides.39 We have
previously shown that IL-17 can directly activate
ECM formation and proliferation by lung
fibroblasts which express IL-17 receptors.40 It is
also noteworthy that in a recent model of acute
exacerbation of fibrosis in mice induced by
repeated injection of bleomycin at day 21 that
both PMNs and IL-17 were elevated in the BALF.41
Taken together, these data suggest that PMNs
may contribute to fibrosis via release of NE and
NETs and one hypothesised reason that IPF
patients may be at risk of increased NETosis to
drive fibrogenesis is because they have a deficit of
prostaglandin E2 (PGE2) in the lung.
42,43 PGE2 is a
molecule we have previously shown to be an
endogenous inhibitor of NETosis.44
Silicosis is a fibrotic lung disease caused by
toxicity due to inhalation of silica glass particles.
PMNs are important for clearance of particulate
matter from the lung, and PMNs are capable of
phagocytising many different particle types,
including silica.45 PMNs are also noted to be
highly recruited to the lungs of rats exposed to
crystalline silica, and this inflammatory response is
associated with changes in profibrotic gene
signatures.46 It is therefore noteworthy that
dasatinib, a tyrosine kinase inhibitor that
improves outcomes postsilica, is associated with
reduced PMN infiltration as well.47 Uptake of
silica by PMNs is able to cause not only NETosis,
but also a form of PMN death called necroptosis,
which also results in release of chromatin and
cellular contents to facilitate fibrosis.45
The data discussed above suggest an important
role of PMNs in generating tissue injury and
driving fibrogenesis in models of noninfectious
acute toxicity caused by bleomycin or silica. In the
third model of pneumonitis and lung fibrosis that
we are considering in this review, infection of
mice at week 5 following a syngeneic stem cell
transplant with cHV68 leads to robust chronic
inflammation and fibrosis that is highly
dependent on IL-17.40 This model is also
characterised by infiltration of the lungs by
monocyte/macrophages and PMNs. Interestingly,
when recruitment of monocytes was reduced by
transplanting with CCR2/ bone marrow, the
fibrotic pathology was worse and the number of
inflammatory granulocytes, including PMNs was
increased, along with higher levels of IL-17 which
as mentioned above can activate fibroblasts.48
However, when PMNs were depleted using anti-
GR1 or anti-Ly6G, the pathologic outcomes were
not different.40,48 While further work is needed, it
seems that in the presence of a replicating
pathogen, that innate immune function may be
necessary for pathogen clearance40,48 and that
other granulocytes (e.g. eosinophils) may be able
to contribute to tissue damage even in the
absence of PMNs. Thinking about potential
antifibrotic therapeutics such as anti-IL-17, it may
be critical that we understand whether or not
there is an infectious component to the aetiology
of the disease before embarking on treatment.
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Macrophages (tissue resident and
inflammatory)
In addition to PMNs, pulmonary macrophages are
also thought to play an important role in driving
fibrotic pathology and this has been one of the
most active areas of recent study. Typically
recruited to initial sites of damage or infection by
inflammatory signals arising from damage to
AECs, pulmonary macrophages are thought to
clear pathogens and debris and orchestrate
further inflammation by the release of
chemokines.49 As discussed above, this pro-
inflammatory recruitment of PMNs may result in
further lung injury. In normal wound healing
responses, however, this pro-inflammatory phase
would be followed by a switch to an
immunosuppressive state to help resolve the
inflammatory response. This immunosuppressive
state is characterised by upregulation of arginase-
1, TGF-b and IL-10 to promote repair. If this
response is transient, then a return to lung
homeostasis is likely. However, if it is prolonged,
arginase-1 metabolism results in the production of
proline, a major amino acid component of
collagen.50 Furthermore, TGF-b stimulates the
production of collagen by fibroblasts.51 Our
laboratory has recently published data to suggest
that IL-10 can sensitise lung AECs to apoptosis
induced by mediators released from activated
macrophages.52 Thus, prolonged accumulation of
these reparative, alternatively activated
macrophages may promote fibrogenesis via
multiple mechanisms.
While the precise roles of different macrophage
subsets in the development of fibrosis have not
yet been fully elucidated, studies suggest that
certain subsets found within the injured lung may
be responsible for driving fibrosis. Monocyte
migration appears to be important in
fibrogenesis, as pulmonary fibrosis was absent in
bleomycin-treated mice lacking the monocyte
chemokine receptor CCR2.53 Additionally,
circulating Ly6Chi monocytes were shown to
enhance the development of fibrosis when
adoptively transferred into bleomycin-treated
recipient mice.54
More recently, reports have also highlighted the
importance of a discrete subset of alveolar
macrophages in driving fibrotic lung
pathology.55,56 In the na€ıve lung, there exists a
self-renewing population of macrophages that
derive from foetal monocytes shortly after birth,
referred to as tissue-resident alveolar
macrophages (TR-AMs), that differ from
macrophages that differentiate from circulating
bone marrow-derived monocytes.57 Following
administration of bleomycin to induce pulmonary
fibrosis in mice, a large portion of the alveolar
macrophage population (distinguished as Siglec
F+) is lost.58 However, during the fibrotic phase of
bleomycin-induced fibrosis, the numbers of
alveolar macrophages increase, concomitant with
the appearance of a population of alveolar
macrophages expressing lower levels of Siglec F.58
Lineage-tracing systems and transcriptome
analyses have characterised these Siglec Flo
macrophages as monocytic in origin, supporting
the idea that bleomycin-induced lung injury
ablates TR-AMs which are replaced by monocyte-
derived alveolar macrophages (Mo-AMs) that
migrate into the alveoli and upregulate Siglec
F.55,56 Expansion of alveolar macrophages has also
been observed in human lung tissue from patients
with pulmonary fibrosis compared to healthy
controls.56 Similar to findings in mice, single-cell
RNA sequencing revealed multiple distinct
macrophage populations in lungs of patients with
fibrosis.59
It is likely that the magnitude of TR-AM
ablation dictates the composition of alveolar
macrophages remaining following resolution of
lung injury. For example, recruitment of Mo-AMs
was observed following diphtheria toxin
depletion of CD11c+ lung cells,60 liposomal
clodronate administration61 and bleomycin
treatment,56 but not in mice treated with LPS,62
indicating that mass ablation of TR-AMs after
severe lung injury may require differentiation of
Mo-AMs to replenish the alveolar macrophage
population. Mo-AMs localise to sites of fibroblast
accumulation following bleomycin-induced lung
injury.55 Of note are recent findings identifying
direct interactions between macrophages and
myofibroblasts via cadherin-11, which possibly
mediate the Mo-AM localisation to the profibrotic
niche,63 and importantly, specific deletion of Mo-
AMs was found to ameliorate fibrosis.55,56 These
findings are further supported in human studies,
wherein macrophages isolated from the lungs of
IPF patients expressed similar profibrotic genes as
their murine Mo-AM homologs.55,56,59
When considering silica-induced fibrosis,
macrophages are the cell type most characterised
by inflammasome activation in response to silica27
and we discussed above how inflammasome
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activation may be potentiated by mechanosensing
and ageing. In contrast, when examining fibrosis
induced by a viral infection post-transplant,
CCR2/ mice, which fail to recruit circulating
monocytes, actually do worse.48 These mice also
showed higher degrees of viral replication which
may exaggerate lung injury to promote fibrosis.
Thus, when considering fibrosis complicated by a
replicating pathogen, it seems the inflammatory
monocytes may serve an important and protective
host defence role. Additionally, as mentioned
above, if monocyte recruitment is inhibited, as in
CCR2/ mice, granulocyte accumulation is further
enhanced with pathologic consequences.
MICROBIAL DRIVERS OF FIBROSIS
Another way the immune system may impact
fibrosis is via regulation of infection and normal
microbiota tone. Both empirical clinical evidence
and epidemiological studies support a link between
IPF and bacterial pneumonia and altered lung
microbiota composition. A 2014 study found that
IPF patients had double the bacterial burden
isolated from BALF compared to healthy controls.64
This and more recent reports have shown that
baseline bacterial burden predicted the rate of
decline in lung function in IPF patients and that
higher bacterial burdens correlated with increased
risk of death.64,65 Another study reported that two
common bacterial genera associated with disease
progression in IPF are Staphylococcus and
Streptococcus.66 Staphylococcus aureus and
Streptococcus pneumoniae are common aetiological
agents of bacterial pneumonia, indicating a
tangible link between infection and IPF disease
progression. The idea of bacterial infection
promoting worse outcomes in IPF patients was
further supported by the results of a small clinical
trial testing the use of the antibiotic co-trimoxazole.
The study found that IPF patients treated with co-
trimoxazole contracted fewer respiratory tract
infections and had significantly reduced all-cause
mortality.67
In preclinical work that allows for more
mechanistic insight, a striking observation was
that germ-free mice lacking an endogenous
microbiome are protected from mortality
following bleomycin-induced fibrosis.65 In
bleomycin-treated conventional mice, dysbiosis of
the lung community characterised by altered
composition and diversity was observed following
lung injury and this dysbiosis persisted through
the development of fibrosis. Altered microbiota
composition in this model was characterised by an
increase in the abundance of members of the
Firmicute phylum which was sustained all the way
through fibrotic development.65 In IPF patients,
dysbiotic lung bacterial communities correlated
with increased levels of profibrotic cytokines and
growth factors (IL-1b, CXCL8, MIP-1a, GCSF, VEGF,
EGF) present in bronchoalveolar lavage fluid.65
Taken together, these studies suggest that
alterations to the lung microbiome, potentially
secondary to dysregulation of innate immune
responses, may drive the progression of lung
fibrosis. The changes to the lung innate immune
profile and microbiota are represented
schematically in Figure 2.
We also recently analysed the alterations to the
lung and gut microbiome within the murine bone
marrow transplantation model of pneumonitis and
fibrosis induced by cHV-68 infection and found
that while the process of transplant alone or viral
infection alone caused transient dysbiosis, the dual
hit was associated with sustained and profound
reductions in lung microbial diversity, but there
was not a lasting effect on gut microbial
diversity.68 The major family change seen was a loss
of Lachnospiraceae in the lungs of mice with
pneumonitis and fibrosis. Interestingly, this family
is a member of the Firmicute phylum and we have
also shown that loss of Firmicutes in the BALF of
human hematopoietic stem cell transplant patients
that are experiencing pulmonary complications are
associated with increased production of numerous
pro-inflammatory cytokines.68 This is contrary to
what was observed in the bleomycin model of
fibrosis,65 demonstrating the heterogeneous
complexity in mechanisms driving different models
of interstitial lung disease. Thus far, the analyses in
the bleomycin and bone marrow transplant models
are at a high level looking only at phyla and family
differences. Future work is needed to determine
whether there are particular bacteria that may be
protective or pathologic and to understand how
the observed dysbiosis may alter production of
metabolites such as short-chain fatty acids which
may further modify host cellular responses.
In addition to possible effects caused by changes
to the indigenous lung community, there is also an
experimental link between fibrotic development
and infection with bacterial pathogens. Infection
of mice with Streptococcus pneumoniae following
development of fibrosis was shown to drive greater
fibrotic progression than that in uninfected mice.69
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This was demonstrated in both the adenovirus-TGF-
b and the surfactant protein C-diphtheria toxin
receptor models of fibrosis, so one hopes that this
finding can be extended to more widely used
models like bleomycin. In this work, fibrotic
progression was found to be mediated by bacterial
expression of the cytotoxin pneumolysin, which
caused increased apoptotic cell death of AECs and
decreased release of prostaglandin E2.
69
Interestingly, infection with Pseudomonas
aeruginosa following bleomycin-induced fibrosis
did not result in fibrotic progression, highlighting
the extreme complexity of potential host–
pathogen interactions in the fibrotic lung.70 Future
work is needed to understand whether the ability
of bacteria to promote fibrogenesis is mediated
solely by a secreted toxin or whether it may involve
differential signalling via PRRs and/or differing
lung cells targeted by infection.
EFFECTS OF FIBROSIS ON INNATE
IMMUNITY
Pulmonary macrophages have the ability to drive
immune responses to respiratory pathogens by
actively phagocytising microbes and producing
reactive oxygen intermediates, nitric oxide (NO),
TNF-a and interferons following stimulation.71
Macrophages also contribute to immune
responses by releasing IL-1 and IL-6, and by
upregulating MHC molecules to more efficiently
present antigen to recruited lymphocytes.71 Thus,
these responses that can be pathologic for tissue
injury are important for host defence. The same
holds true for PMNs – many of the responses that
drive excessive tissue injury are essential for
adequate pathogen clearance. NETs ensnare and
kill extracellular microbes,72 and NE is an
antimicrobial peptide important in defence
against Gram-negative bacteria.73 While these
responses can be important for initial tissue
injury, paradoxically, there is evidence that in
established fibrosis, innate immune cells may lose
the ability to properly respond to respiratory
pathogens (Figure 3).
Collagen is the predominant component of scar
tissue and is found in high levels in fibrotic lungs.
Macrophages and PMNs have various ways of
sensing collagen itself as well as extracellular
matrix stiffness, and studies have indicated that
the signalling pathways responding to these
environmental cues can alter cellular function.
Leucocyte-associated Ig-like receptor 1 (LAIR-1), an
inhibitory receptor that binds to native collagen,
was shown to promote alternative activation of
immunoregulatory, tissue-restorative macrophages
and inhibit pro-inflammatory macrophage
differentiation.74 LAIR-1 signalling also reduced
human neutrophil NET formation following
ex vivo treatment with agonistic anti-LAIR-1
AECI 
Healthy lung  Fibroc lung  
Alveolar airspace  
Intersum 
Healthy 
microbiome 
TR-AM 
Pro-ﬁbroc factor 
ECM 
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Dysbioc 
microbiome 
Exogenous 
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Figure 2. Schematic depicting the changes to the lung innate immune profile and microbiota following the development of fibrosis. In a healthy
lung, the alveolar airspace is characterised by tissue-resident alveolar macrophages (TR-AMs) and a diverse microbiome with limited soluble
mediator production and extracellular matrix (ECM) deposition. In a fibrotic lung, however, monocyte-derived alveolar macrophages (Mo-AMs)
migrate into the lungs to replace the lost TR-AMs. Fibroblasts also accumulate and start to lay down ECM which restricts gas exchange and
expansion of the lung during inspiration. In addition, there is a dysbiosis of the indigenous microbiome resulting in decreased diversity,
enrichment of certain phyla of bacteria, and an overall increase in bacterial burden. These changes are associated with increased levels of
profibrotic cytokines and growth factors. Lastly, the presence of certain exogenous microbes has been associated with the development of
fibrosis, which could possibly lead to the worsening of disease.
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antibodies.75 Mice lacking tyrosine kinase collagen
receptors discoidin domain receptors 1 and 2
(DDR1 and DDR2) are known to be protected
from pulmonary fibrosis76,77; however, these
receptors also appear to regulate the function of
immune cells. DDR1 signalling is important in
macrophage migration and production of NO,
two functions key to the ability of macrophages
to respond to pathogens.78,79 Neutrophil
chemotaxis is also regulated by DDR2 when
cultured in 3D matrices.80 Additionally, transient
receptor potential vanilloid 4 or TRPV4, an ion
channel sensitive to changes in collagen stiffness,
has been shown to regulate macrophage
phagocytosis.81 Increasing levels of collagen can
be found in the lungs as the development of
fibrosis progresses, so it is plausible that collagen
and matrix stiffness can mediate the function of
immune cells through the actions of the
aforementioned receptors to alter their responses
to respiratory infections.
Similarly, it has been known for more than
30 years that in vitro administration of silica to
macrophages and neutrophils decreases their
viability, likely due to lysosomal disruption, and can
limit their ability to phagocytise bacteria and to kill
intracellular pathogens.82 More recent studies have
shown that larger silica particles decrease the
ability of alveolar macrophages to produce NO and
reactive oxygen species83; however, the ultimate
impact on cell function relates to the size of the
silica particle that is ingested, with submicron
particles being more pro-inflammatory.84
With regard to the cHV-68 model of
pneumonitis and fibrosis post-transplant, the
process of transplantation impairs the phagocytic
and killing functions of the alveolar macrophages
and PMNs85 and as discussed above, a failure to
recruit inflammatory monocytes impairs clearance
of lytic cHV-68.48 However, these alterations may
be impacted more by the process of stem cell
transplant rather than by the alterations in lung
ECM and further research is needed to evaluate
this. This model has also been shown to be
impacted by alterations in Notch signalling,
specifically by loss of delta-like 4 ligand on
dendritic cells and loss of the Notch 1 and Notch 2
receptors on T cells.86 This loss of Notch signalling
which appears to be a consequence of both the
radiation conditioning and the viral infection
drives the increased IL-17 to promote fibrogenesis.
When taken together, there is now a body of
literature that clearly supports the important role
of innate immune cells in stimulating tissue injury
and fibrogenesis, but it also seems that innate
immune cells residing in a fibrotic
microenvironment may be less equipped to fight
off pulmonary infection. We speculate that this
two-way signalling may be another mechanism
that promotes the progressive nature of lung
fibrosis whereby innate immune cells trigger
initial injury, but then undergo reprogramming
within the fibrotic niche that impairs host
defence, allowing for infections or alterations to
the microbiota that ultimately further damage
and scar the lung.
Macrophage 
Collagen 
Collagen receptors 
Silica 
Stem cell 
transplant 
Inhibion of pro-inﬂammatory diﬀerenaon 
Altered NO and ROS producon 
Altered migraon 
Decreased viability 
Altered phagocytosis 
Figure 3. Effects of fibrosis on macrophage function. Evidence suggests that the development of fibrosis may impact the ability of innate
immune cells to respond to respiratory infections. Macrophage collagen receptor signalling has been linked to the inhibition of pro-inflammatory
macrophage differentiation and altered migration, nitric oxide (NO) production and phagocytosis. Silica has been shown to decrease macrophage
viability and alter phagocytosis, NO and reactive oxygen species (ROS) production. Stem cell transplant impairs macrophage phagocytosis and
killing functions due to upregulation of prostaglandin E2 production.
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SUMMARY AND RECOMMENDATIONS
FOR FUTURE RESEARCH
In this review, we summarise the known
contributions of the innate immune system to
fibrotic progression, highlighting the importance
of PMNs and macrophages in driving disease in
three unique models of fibrogenesis. The roles of
innate immune pattern recognition receptors and
inflammasomes were considered. We also discuss
the direct contributions of PMNs and
macrophages in both lung injury and driving
fibroblast proliferation and ECM production to
mediate aberrant wound repair. In addition, the
role of microbial influences on disease (both
commensal and exogenous) is examined. To
conclude, we speculate upon how the ability of
innate immune cells to respond properly to
respiratory pathogens may be compromised
following the development of fibrosis.
Despite this compilation of research, much is
still unknown about the precise roles of innate
immune cells in fibrotic lung disease. While it is
thought that fibrosis is perpetuated by injury to
the lung, how PMNs fit into the picture is much
less clear. Do PMNs drive the initial lung injury or
is their presence in the lungs a response to an
external stimulus (such as an occult respiratory
infection) that initiates the injury? Are they
needed for clearance of debris, or do they die in
tissue via NETosis and necroptosis to promote
fibroblast activation? If so, is this a common
mechanism in all forms of tissue fibrosis?
Macrophages are also known to play an
important role in regulating wound repair;
however, nonpathological wound repair
terminates in a return to tissue homeostasis. What
is it about the fibrotic microenvironment that
dictates whether a macrophage adopts a tissue-
restorative phenotype transiently to allow a
return to homeostasis versus becoming
pathologically activated to promote fibrosis? In
addition, the profibrotic function of the recently
characterised Mo-AM subtype has been
suggested,55,56 but there is still much to learn
about the mechanism of their contributions to
disease. While we have discussed some potential
hypotheses to explain the progressive nature of
IPF and other fibrotic lung diseases, there is no
concrete evidence yet for why the disease
progresses in humans but is largely self-resolving
in our animal models. Does progressive fibrosis
require the presence of human-residing
microbiota or are there important differences in
how injury and infection are sensed in mice and
humans? While there is a clear association
between IPF and the diversity, composition, and
overall burden of bacteria found within the
lung,64,65 we can only speculate on how dysbiosis
of the indigenous lung community specifically
contributes to disease progression, and whether
this dysbiosis is the result of altered immunity or
vice versa is still not clear.
Additionally, the complicated interplay between
respiratory pathogens and innate immunity in the
fibrotic lung is extremely understudied. As one
study showed, infection with Streptococcus
pneumoniae following fibrosis actually increased
fibrogenesis through cytotoxin-mediated AEC
death,69 supporting a role for bacterial
pneumonia driving aberrant wound repair.
However, this does not hold true for every
bacterial pathogen as Pseudomonas aeruginosa
did not exacerbate fibrosis,70 indicating that this
effect is likely pathogen-specific and highlighting
the need for additional research examining host–
pathogen interactions in the fibrotic lung. One
may speculate that certain bacterial species
interact with innate immune receptors to perhaps
initiate pro-inflammatory or profibrotic signalling
to promote fibrogenesis, but it must also be
remembered that some interactions of DAMPs
with TLRs seem to promote repair as well.18 How
TLR4 signalling may be both restorative and
pathologic is not understood.
Lastly, there is a preponderance of evidence to
support the idea that the development of fibrosis
alters the function of innate immune cells,
possibly making IPF patients more susceptible to
respiratory infections in the first place. It is well-
known clinically that IPF patients that acquire
respiratory infections have very poor
outcomes.12,87 While respiratory pathogens like
Pseudomonas aeruginosa may not drive the
deposition of additional ECM following infection,
they could be the cause of declining lung
function in IPF patients due to the induction of
inflammation and the inflammatory exudate
further limiting gas exchange. This important
complication has received relatively little
attention in the field of IPF research as there has
been a strong focus on studying the
‘noninfectious’ causes of acute exacerbations.
Therefore, future effort should consider
evaluating the interactions between respiratory
pathogens and the innate immune system within
2019 | Vol. 8 | e1065
Page 10
ª 2019 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of
Australian and New Zealand Society for Immunology Inc.
Lung innate immunity and fibrosis HI Warheit-Niemi et al.
the fibrotic lung to better understand how to
treat these patients, and to understand that their
immune systems may in fact be characterised by
impairment, rather than overt activation in late
stages of disease.
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